128 related articles for article (PubMed ID: 9815910)
1. Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model.
Xu Y; Scheinberg DA
Clin Cancer Res; 1995 Oct; 1(10):1179-87. PubMed ID: 9815910
[TBL] [Abstract][Full Text] [Related]
2. Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice.
Xu Y; Xu Q; Rosenblum MG; Scheinberg DA
Leukemia; 1996 Feb; 10(2):321-6. PubMed ID: 8637241
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate.
Bernstein ID
Leukemia; 2000 Mar; 14(3):474-5. PubMed ID: 10720144
[TBL] [Abstract][Full Text] [Related]
4. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a transplantable human myeloid BALB/c nude mouse model.
Wei YM; Lin JH; Xia R; Lan JC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):596-600. PubMed ID: 16129041
[TBL] [Abstract][Full Text] [Related]
6. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.
Caron PC; Co MS; Bull MK; Avdalovic NM; Queen C; Scheinberg DA
Cancer Res; 1992 Dec; 52(24):6761-7. PubMed ID: 1458463
[TBL] [Abstract][Full Text] [Related]
7. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity.
Caron PC; Jurcic JG; Scott AM; Finn RD; Divgi CR; Graham MC; Jureidini IM; Sgouros G; Tyson D; Old LJ
Blood; 1994 Apr; 83(7):1760-8. PubMed ID: 8142644
[TBL] [Abstract][Full Text] [Related]
8. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker.
Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Flowers DA; Bernstein I
Bioconjug Chem; 2002; 13(1):40-6. PubMed ID: 11792177
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.
Duzkale H; Pagliaro LC; Rosenblum MG; Varan A; Liu B; Reuben J; Wierda WG; Korbling M; McMannis JD; Glassman AB; Scheinberg DA; Freireich EJ
Biol Blood Marrow Transplant; 2003 Jun; 9(6):364-72. PubMed ID: 12813444
[TBL] [Abstract][Full Text] [Related]
10. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
Chen J; Zhou JH; Ball ED
Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
[TBL] [Abstract][Full Text] [Related]
11. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias.
McGraw KJ; Rosenblum MG; Cheung L; Scheinberg DA
Cancer Immunol Immunother; 1994 Dec; 39(6):367-74. PubMed ID: 8001024
[TBL] [Abstract][Full Text] [Related]
12. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells.
Chen P; Wang J; Hope K; Jin L; Dick J; Cameron R; Brandwein J; Minden M; Reilly RM
J Nucl Med; 2006 May; 47(5):827-36. PubMed ID: 16644753
[TBL] [Abstract][Full Text] [Related]
13. [Monoclonal antibody therapies for acute leukemia].
Takeshita A; Ono R
Rinsho Ketsueki; 2002 May; 43(5):353-6. PubMed ID: 12096485
[No Abstract] [Full Text] [Related]
14. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia.
Caron PC; Schwartz MA; Co MS; Queen C; Finn RD; Graham MC; Divgi CR; Larson SM; Scheinberg DA
Cancer; 1994 Feb; 73(3 Suppl):1049-56. PubMed ID: 8306247
[TBL] [Abstract][Full Text] [Related]
15. Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells.
Vitale C; Romagnani C; Puccetti A; Olive D; Costello R; Chiossone L; Pitto A; Bacigalupo A; Moretta L; Mingari MC
Proc Natl Acad Sci U S A; 2001 May; 98(10):5764-9. PubMed ID: 11320212
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome.
Matthews DC
Leukemia; 1998 Sep; 12 Suppl 1():S33-6. PubMed ID: 9777893
[TBL] [Abstract][Full Text] [Related]
17. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM
Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
[TBL] [Abstract][Full Text] [Related]
18. Antibody-targeted chemotherapy of relapsed AML.
Mineur P; Lejeune C; Hennaux V; Eten C
Br J Haematol; 2003 Apr; 121(1):195-6. PubMed ID: 12670356
[No Abstract] [Full Text] [Related]
19. Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia.
Caron PC; Scheinberg DA
Leuk Lymphoma; 1993; 11 Suppl 2():1-6. PubMed ID: 8124221
[TBL] [Abstract][Full Text] [Related]
20. Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones.
Firat H; Favier R; Adam M; Leverger G; Landman-Parker J; Cayre Y; Douay L
Leuk Lymphoma; 2001 Aug; 42(4):675-82. PubMed ID: 11697497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
